

**$\beta$ -Amyloid (1-43) (E8C2D) Rabbit mAb**

**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IF-F	H	Endogenous	6	Rabbit IgG	#P05067	351

**Product Usage Information****Application**

Western Blotting  
Immunofluorescence (Frozen)

**Dilution**

1:1000  
1:200 - 1:800

**Storage**

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100  $\mu$ g/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at  $-20^{\circ}\text{C}$ . Do not aliquot the antibody.

For a carrier free (BSA and azide free) version of this product see product #29691.

**Specificity/Sensitivity**

$\beta$ -Amyloid (1-43) (E8C2D) Rabbit mAb recognizes endogenous levels of total human  $\text{A}\beta$ -43 protein. This product detects transgenically expressed human APP in mouse models. This antibody weakly cross-reacts with human  $\text{A}\beta$ -42 protein.

**Species predicted to react based on 100% sequence homology**

Mouse

**Source / Purification**

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy of human  $\beta$ -Amyloid (1-43) protein.

**Background**

Amyloid  $\beta$  ( $\text{A}\beta$ ) precursor protein (APP) is a 100-140 kDa transmembrane glycoprotein that exists as several isoforms (1). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (1). The extracellular deposition and accumulation of the released  $\text{A}\beta$  fragments form the main components of amyloid plaques in Alzheimer's disease (1). APP can be phosphorylated at several sites, which may affect the proteolytic processing and secretion of this protein (2-5). Phosphorylation at Thr668 (a position corresponding to the APP695 isoform) by cyclin-dependent kinase is cell-cycle dependent and peaks during G2/M phase (4). APP phosphorylated at Thr668 exists in adult rat brain and correlates with cultured neuronal differentiation (5,6).  $\text{A}\beta$ 43 has been suggested as a biomarker in early onset of Alzheimer's disease, where patients have lower levels of  $\text{A}\beta$ 43 in cerebrospinal fluid (7,8,9). Several studies have shown that  $\text{A}\beta$  toxicity of  $\text{A}\beta$ 43 is as high as  $\text{A}\beta$ 42 or  $\text{A}\beta$ 40 in different models of Alzheimer's disease, including mouse models and human disease. (10).

**Background References**

- Selkoe, D.J. (1996) *J Biol Chem* 271, 18295-8.
- Caporaso, G.L. et al. (1992) *Proc Natl Acad Sci USA* 89, 3055-9.
- Hung, A.Y. and Selkoe, D.J. (1994) *EMBO J* 13, 534-42.
- Suzuki, T. et al. (1994) *EMBO J* 13, 1114-22.
- Ando, K. et al. (1999) *J Neurosci* 19, 4421-7.
- Iijima, K. et al. (2000) *J Neurochem* 75, 1085-91.
- Lauridsen, C. et al. (2017) *Front Aging Neurosci* 9, 210.
- Almdahl, I.S. et al. (2017) *Front Aging Neurosci* 9, 9.
- Pachahara, S.K. et al. (2015) *PLoS One* 10, e0136567.
- Trambauer, J. et al. (2017) *Methods Enzymol* 584, 157-183.

**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at  $4^{\circ}\text{C}$  with gentle shaking, overnight.

**Applications Key**

**W:** Western Blotting **IF-F:** Immunofluorescence (Frozen)

**Cross-Reactivity Key**

**H:** Human

## Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Alexa Fluor is a registered trademark of Life Technologies Corporation.

All other trademarks are the property of their respective owners. Visit [cellsignal.com/trademarks](http://cellsignal.com/trademarks) for more information.

## Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.